Dash Bio Raises $30 Million to Modernise Drug Development Infrastructure
Dash Bio Raises $30 Million To Expand Automated Bioanalysis Platform Life sciences venture firms invested to accelerate innovation across Dash Bio’s Automated Bioanalysis Platform for pharmaceutical companies. Oak HC/FT led The post Dash Bio Raises $30 Million to Modernise Drug Development Infrastructure appeared first on Ventureburn .
Biotechnology company Dash Bio has secured $30 million in funding to enhance its automated bioanalysis platform, designed to revolutionize drug development processes for pharmaceutical companies. The investment round, led by Oak HC/FT, was co-led by existing investors Freestyle Capital and Swift Ventures. This funding will be utilized for laboratory expansion, enhancement of proprietary software, and the introduction of additional bioanalysis testing services worldwide.
Dash Bio's platform aims to expedite drug discovery by increasing testing capacity during both early and late-stage therapeutic development programs.
The company's automated bioanalysis platform has significantly reduced laboratory testing timelines from months to days, utilizing cutting-edge scientific workflow automation technology. Dash Bio's system currently manages various laboratory assays, including ELISA, MSD, qPCR, ddPCR, and LC-MS, while cutting down laboratory processing times and manual labor.
Operating from a 24,000-square-foot GLP facility, Dash Bio boasts a fully automated, high-efficiency laboratory environment that delivers preclinical testing results within days, as opposed to the months typically required by conventional Contract Research Organizations (CROs).
Dash Bio's innovative platform has already gained significant commercial traction, with over 30 customers, including four of the world's top 15 pharmaceutical companies, signing contracts. These customers have praised the platform for its rapid turnaround times and transparent pricing, which outperform traditional laboratory service providers.
As pharmaceutical companies strive to accelerate clinical development and streamline research operations, the demand for Dash Bio's automated laboratory infrastructure is expected to grow exponentially.
The funding round was bolstered by Oak HC/FT's confidence in Dash Bio's team, recognizing their expertise in building digital and automation infrastructure at Moderna. The company's leadership team, including CEO Dave Johnson, COO Ander Tallett, and CSO Ely Porter, established Dash Bio on the belief that scientific progress should dictate development timelines rather than laboratory limitations.
As pharmaceutical companies increasingly adopt advanced technologies throughout their research and development processes, Dash Bio's automated laboratory services are poised to play a crucial role in accelerating the delivery of new medicines to patients.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
